Let's Do the Numbers:
Analysts are looking ahead to a positive EPS reading of 8 cents per share and revenues of $1.94 billion. We'll have to wait for Monday to see if Boston Scientific falls in line with analyst expectations and reports an estimated increase in both EPS and revenue from the year-ago quarter.Here's how the company's reported EPS has stacked up against analyst estimates in the past:
Quarter | Q1 | Q4 | Q3 | Q2 |
EPS Estimate | 4 cents | 10 cents | 6 cents | 3 cents |
EPS Actual | 14 cents | 20 cents | 12 cents | 6 cents |
Stock Performance:
At last check, shares of Boston Scientific were trading at $7.28. Shares are down 3.8% year to date.Average Stock Rating:
The average rating by analysts for Boston Scientific is a Hold. The strength of this rating has declined slightly over the past three months.Competitors:
Wondering how Boston Scientific compares to rivals in the same sector? Here are a few of the company's peers.- Abbott Laboratories ABT: Hold with a $0.91 recent quarter EPS
- Johnson & Johnson JNJ: Moderate Buy with a $1.35 recent quarter EPS
Boston Scientific is in the medical products industry, which has experienced price/earnings growth of 1.4%.
Finally, a description of the main business areas of the company, in case you need a little refresher: Boston Scientific, Inc. offers medical devices used in interventional cardiology, cardiac rhythm management, peripheral interventions, endoscopy, gynecology, electrophysiology, neurovascular intervention and neuromodulation.
Take Action:
Now that you have reviewed all the numbers, be ready to move if the upcoming Boston Scientific earnings report has any surprises. Also, come back to Benzinga after the announcement for a full recap and a guide to your next steps.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.